Context Therapeutics Ownership 2024 | Who Owns Context Therapeutics Now?

Overview Forecast RevenueFinancials Chart

Institutional Ownership

24.65%

Insider Ownership

2.78%

Retail Ownership

72.57%

Institutional Holders

25.00

Context Therapeutics Institutional Shareholders

Institutional Shareholders by % of Total Shares

Name	% Total Shares	% Total Assets	Current Shares	Change Amount	Change %	Market Value	Date
OPALEYE MANAGEMENT INC.	6.94%	0.35%	1,108,357	133,357	13.68%	1,529,533	Mar 31, 2024
ALLY BRIDGE GROUP (NY) LLC	4.55%	0.56%	725,951	-	-	1,001,812	Mar 31, 2024
VANGUARD GROUP INC	3.75%	-	598,303	2,291	0.38%	825,658	Mar 31, 2024
AFFINITY ASSET ADVISORS, LLC	2.06%	0.06%	328,817	-	-	453,767	Mar 31, 2024
UBS OCONNOR LLC	1.86%	0.03%	296,675	-	-	409,412	Mar 31, 2024
ADAR1 CAPITAL MANAGEMENT, LLC	1.29%	0.06%	205,934	205,934	100.00%	284,189	Mar 31, 2024
HIGHTOWER ADVISORS, LLC	0.79%	0.00%	125,852	-	-	174,000	Mar 31, 2024
BRIDGEWAY CAPITAL MANAGEMENT, LLC	0.66%	0.00%	105,809	-	-	146,016	Mar 31, 2024
MILL CREEK CAPITAL ADVISORS, LLC	0.66%	0.00%	104,631	-	-	144,391	Mar 31, 2024
GEODE CAPITAL MANAGEMENT, LLC	0.63%	-	101,072	3,832	3.94%	139,547	Mar 31, 2024
RENAISSANCE TECHNOLOGIES LLC	0.25%	0.00%	39,900	7,700	23.91%	55,000	Mar 31, 2024
NORTHERN TRUST CORP	0.23%	-	37,219	-	-	51,362	Mar 31, 2024
CLEAR HARBOR ASSET MANAGEMENT, LLC	0.23%	0.00%	36,000	-	-	49,680	Mar 31, 2024
STATE STREET CORP	0.21%	-	32,907	-	-	45,412	Mar 31, 2024
SUSQUEHANNA INTERNATIONAL GROUP, LLP	0.14%	-	22,389	22,389	100.00%	30,897	Mar 31, 2024
SHEETS SMITH WEALTH MANAGEMENT	0.13%	0.00%	20,000	-	-	27,600	Mar 31, 2024
CITADEL ADVISORS LLC	0.09%	-	15,041	-839	-5.28%	20,757	Mar 31, 2024
JEFFERIES FINANCIAL GROUP INC.	0.07%	0.00%	11,453	11,453	100.00%	15,805	Mar 31, 2024
XTX TOPCO LTD	0.06%	0.00%	10,261	10,261	100.00%	14,160	Mar 31, 2024
TOWER RESEARCH CAPITAL LLC (TRC)	0.04%	0.00%	6,357	-298	-4.48%	8,773	Mar 31, 2024

Context Therapeutics's largest institutional shareholder is OPALEYE MANAGEMENT INC., holding 6.94% of the company's total share outstanding, currently valued at $1.53M. The top 10 institutional shareholders own together 23.18% of the company.

Institutional Shareholders by % of Total Assets

Name	% Total Shares	% Total Assets	Current Shares	Change Amount	Change %	Market Value	Date
ALLY BRIDGE GROUP (NY) LLC	4.55%	0.56%	725,951	-	-	1,001,812	Mar 31, 2024
OPALEYE MANAGEMENT INC.	6.94%	0.35%	1,108,357	133,357	13.68%	1,529,533	Mar 31, 2024
ADAR1 CAPITAL MANAGEMENT, LLC	1.29%	0.06%	205,934	205,934	100.00%	284,189	Mar 31, 2024
AFFINITY ASSET ADVISORS, LLC	2.06%	0.06%	328,817	-	-	453,767	Mar 31, 2024
UBS OCONNOR LLC	1.86%	0.03%	296,675	-	-	409,412	Mar 31, 2024
CLEAR HARBOR ASSET MANAGEMENT, LLC	0.23%	0.00%	36,000	-	-	49,680	Mar 31, 2024
MILL CREEK CAPITAL ADVISORS, LLC	0.66%	0.00%	104,631	-	-	144,391	Mar 31, 2024
SHEETS SMITH WEALTH MANAGEMENT	0.13%	0.00%	20,000	-	-	27,600	Mar 31, 2024
BRIDGEWAY CAPITAL MANAGEMENT, LLC	0.66%	0.00%	105,809	-	-	146,016	Mar 31, 2024
XTX TOPCO LTD	0.06%	0.00%	10,261	10,261	100.00%	14,160	Mar 31, 2024
HIGHTOWER ADVISORS, LLC	0.79%	0.00%	125,852	-	-	174,000	Mar 31, 2024
TOWER RESEARCH CAPITAL LLC (TRC)	0.04%	0.00%	6,357	-298	-4.48%	8,773	Mar 31, 2024
JEFFERIES FINANCIAL GROUP INC.	0.07%	0.00%	11,453	11,453	100.00%	15,805	Mar 31, 2024
RENAISSANCE TECHNOLOGIES LLC	0.25%	0.00%	39,900	7,700	23.91%	55,000	Mar 31, 2024
RETIREMENT GROUP, LLC	0.00%	0.00%	155	-	-	214	Mar 31, 2024
VANGUARD GROUP INC	3.75%	-	598,303	2,291	0.38%	825,658	Mar 31, 2024
GEODE CAPITAL MANAGEMENT, LLC	0.63%	-	101,072	3,832	3.94%	139,547	Mar 31, 2024
NORTHERN TRUST CORP	0.23%	-	37,219	-	-	51,362	Mar 31, 2024
SUSQUEHANNA INTERNATIONAL GROUP, LLP	0.14%	-	22,389	22,389	100.00%	30,897	Mar 31, 2024
ADVISOR GROUP HOLDINGS, INC.	0.01%	-	1,500	-	-	2,070,000	Mar 31, 2024

The largest Context Therapeutics shareholder by % of total assets is ALLY BRIDGE GROUP (NY) LLC. The company owns 725.95K shares of Context Therapeutics (CNTX), representing 0.56% of its total assets.

Institutional Buyers

Name	% Total Shares	% Total Assets	Current Shares	Change Amount	Change %	Market Value	Date
ADAR1 CAPITAL MANAGEMENT, LLC	1.29%	0.06%	205,934	205,934	100.00%	284,189	Mar 31, 2024
OPALEYE MANAGEMENT INC.	6.94%	0.35%	1,108,357	133,357	13.68%	1,529,533	Mar 31, 2024
SUSQUEHANNA INTERNATIONAL GROUP, LLP	0.14%	-	22,389	22,389	100.00%	30,897	Mar 31, 2024
JEFFERIES FINANCIAL GROUP INC.	0.07%	0.00%	11,453	11,453	100.00%	15,805	Mar 31, 2024
XTX TOPCO LTD	0.06%	0.00%	10,261	10,261	100.00%	14,160	Mar 31, 2024
RENAISSANCE TECHNOLOGIES LLC	0.25%	0.00%	39,900	7,700	23.91%	55,000	Mar 31, 2024
GEODE CAPITAL MANAGEMENT, LLC	0.63%	-	101,072	3,832	3.94%	139,547	Mar 31, 2024
VANGUARD GROUP INC	3.75%	-	598,303	2,291	0.38%	825,658	Mar 31, 2024
	0.00%	-	400	400	100.00%	552	Mar 31, 2024
JPMORGAN CHASE & CO	0.00%	-	33	10	43.48%	46	Mar 31, 2024
WELLS FARGO & COMPANY/MN	0.00%	-	116	2	1.75%	160,000	Mar 31, 2024
STATE STREET CORP	0.21%	-	32,907	-	-	45,412	Mar 31, 2024
ADVISOR GROUP HOLDINGS, INC.	0.01%	-	1,500	-	-	2,070,000	Mar 31, 2024
NORTHERN TRUST CORP	0.23%	-	37,219	-	-	51,362	Mar 31, 2024
RETIREMENT GROUP, LLC	0.00%	0.00%	155	-	-	214	Mar 31, 2024
HIGHTOWER ADVISORS, LLC	0.79%	0.00%	125,852	-	-	174,000	Mar 31, 2024
BRIDGEWAY CAPITAL MANAGEMENT, LLC	0.66%	0.00%	105,809	-	-	146,016	Mar 31, 2024
SHEETS SMITH WEALTH MANAGEMENT	0.13%	0.00%	20,000	-	-	27,600	Mar 31, 2024
MILL CREEK CAPITAL ADVISORS, LLC	0.66%	0.00%	104,631	-	-	144,391	Mar 31, 2024
CLEAR HARBOR ASSET MANAGEMENT, LLC	0.23%	0.00%	36,000	-	-	49,680	Mar 31, 2024

As of Mar 31 2024, Context Therapeutics's largest institutional buyer is ADAR1 CAPITAL MANAGEMENT, LLC. The company purchased 205.93K stocks of CNTX, valued at $284.19K.

Institutional Sellers

Name	% Total Shares	% Total Assets	Current Shares	Change Amount	Change %	Market Value	Date
ASPIRE WEALTH MANAGEMENT CORP	-	-	-	-10,000	-100.00%	-	Mar 31, 2024
UBS GROUP AG	-	-	-	-9,490	-100.00%	-	Mar 31, 2024
CITADEL ADVISORS LLC	0.09%	-	15,041	-839	-5.28%	20,757	Mar 31, 2024
TOWER RESEARCH CAPITAL LLC (TRC)	0.04%	0.00%	6,357	-298	-4.48%	8,773	Mar 31, 2024
BANK OF AMERICA CORP /DE/	-	-	-	-109	-100.00%	-	Mar 31, 2024
ALLY BRIDGE GROUP (NY) LLC	4.55%	0.56%	725,951	-	-	1,001,812	Mar 31, 2024
AFFINITY ASSET ADVISORS, LLC	2.06%	0.06%	328,817	-	-	453,767	Mar 31, 2024
UBS OCONNOR LLC	1.86%	0.03%	296,675	-	-	409,412	Mar 31, 2024
CLEAR HARBOR ASSET MANAGEMENT, LLC	0.23%	0.00%	36,000	-	-	49,680	Mar 31, 2024
MILL CREEK CAPITAL ADVISORS, LLC	0.66%	0.00%	104,631	-	-	144,391	Mar 31, 2024
SHEETS SMITH WEALTH MANAGEMENT	0.13%	0.00%	20,000	-	-	27,600	Mar 31, 2024
BRIDGEWAY CAPITAL MANAGEMENT, LLC	0.66%	0.00%	105,809	-	-	146,016	Mar 31, 2024
HIGHTOWER ADVISORS, LLC	0.79%	0.00%	125,852	-	-	174,000	Mar 31, 2024
RETIREMENT GROUP, LLC	0.00%	0.00%	155	-	-	214	Mar 31, 2024
NORTHERN TRUST CORP	0.23%	-	37,219	-	-	51,362	Mar 31, 2024
ADVISOR GROUP HOLDINGS, INC.	0.01%	-	1,500	-	-	2,070,000	Mar 31, 2024
STATE STREET CORP	0.21%	-	32,907	-	-	45,412	Mar 31, 2024
WELLS FARGO & COMPANY/MN	0.00%	-	116	2	1.75%	160,000	Mar 31, 2024
JPMORGAN CHASE & CO	0.00%	-	33	10	43.48%	46	Mar 31, 2024
	0.00%	-	400	400	100.00%	552	Mar 31, 2024

As of Mar 31 2024, Context Therapeutics's biggest institutional seller is ASPIRE WEALTH MANAGEMENT CORP. The company sold -10.00K shares of CNTX, valued at -.

Institutional New positions

Name	% Total Shares	% Total Assets	Current Shares	Change Amount	Change %	Market Value	Date
ADAR1 CAPITAL MANAGEMENT, LLC	1.29%	0.06%	205,934	205,934	100.00%	284,189	Mar 31, 2024
SUSQUEHANNA INTERNATIONAL GROUP, LLP	0.14%	-	22,389	22,389	100.00%	30,897	Mar 31, 2024
JEFFERIES FINANCIAL GROUP INC.	0.07%	0.00%	11,453	11,453	100.00%	15,805	Mar 31, 2024
	0.00%	-	400	400	100.00%	552	Mar 31, 2024

Context Therapeutics's largest new institutional shareholder by number of shares is ADAR1 CAPITAL MANAGEMENT, LLC, purchased 205.93K shares, valued at $284.19K, as of undefined.

Institutional Sold Out

Name	% Total Shares	% Total Assets	Current Shares	Change Amount	Change %	Market Value	Date
ASPIRE WEALTH MANAGEMENT CORP	-	-	-	-10,000	-100.00%	-	Mar 31, 2024
UBS GROUP AG	-	-	-	-9,490	-100.00%	-	Mar 31, 2024
BANK OF AMERICA CORP /DE/	-	-	-	-109	-100.00%	-	Mar 31, 2024

Context Therapeutics's largest sold out institutional shareholder by shares sold is ASPIRE WEALTH MANAGEMENT CORP, sold -10.00K shares, valued at -, as of undefined.

Context Therapeutics Mutual Fund Holders

Name	% Total Assets	Total Shares	Change Amount	Change %	Date
BRIDGEWAY FUNDS INC	0.04%	105,809	-	-	Dec 29, 2023
VANGUARD INDEX FUNDS	0.00%	618,624	25,133	4.23%	Dec 31, 2023
FIDELITY CONCORD STREET TRUST	0.00%	95,595	3,272	3.54%	Feb 29, 2024
NATIONWIDE MUTUAL FUNDS	0.00%	9,400	-	-	Jan 31, 2024
iSHARES TRUST	0.00%	15,945	-	-	Feb 29, 2024
EQ ADVISORS TRUST	0.00%	1,016	-	-	Dec 31, 2023

Context Therapeutics's largest mutual fund holder by % of total assets is "BRIDGEWAY FUNDS INC", owning 105.81K shares, compromising 0.04% of its total assets.

Context Therapeutics Institutional Ownership Trends

Institutional Holdings Trend

Date	Holdings	Change %
31 Mar, 24	25	8.70%
31 Dec, 23	23	4.55%
30 Sep, 23	22	4.76%
30 Jun, 23	21	10.53%
31 Mar, 23	19	-13.64%
31 Dec, 22	22	10.00%
30 Sep, 22	20	17.65%
30 Jun, 22	17	41.67%
31 Mar, 22	12	-25.00%
31 Dec, 21	16	-

As of 31 Mar 24, 25 institutions are holding Context Therapeutics's shares, representing an increase of 8.70% compared to the previous quarter.

Shares Outstanding Trend

Date	Shares Outstanding	Change %
31 Mar, 24	3,935,132	10.59%
31 Dec, 23	3,558,239	38.01%
30 Sep, 23	2,578,256	15.16%
30 Jun, 23	2,238,766	77.40%
31 Mar, 23	1,262,007	-67.50%
31 Dec, 22	3,882,945	-5.68%
30 Sep, 22	4,116,702	13.04%
30 Jun, 22	3,641,962	25.39%
31 Mar, 22	2,904,420	-18.17%
31 Dec, 21	3,549,370	-

Context Therapeutics (CNTX) has 3.94M shares outstanding as of 31 Mar 24, up 10.59% compared to the previous quarter.

Institutional Ownership Trend

Date	Ownership %	Change %
31 Mar, 24	24.65%	4.96%
31 Dec, 23	22.29%	8.55%
30 Sep, 23	16.15%	8.21%
30 Jun, 23	14.02%	22.44%
31 Mar, 23	7.90%	1.34%
31 Dec, 22	24.32%	3.66%
30 Sep, 22	25.78%	4.96%
30 Jun, 22	22.81%	6.89%
31 Mar, 22	18.19%	1.51%
31 Dec, 21	34.76%	-

As of 31 Mar 24, Context Therapeutics is held by 24.65% institutional shareholders, representing a 4.96% growth compared to 31 Dec 23.

Institutional Increased Positions Trend

Date	Increased Positions	Change %
31 Mar, 24	11	22.22%
31 Dec, 23	9	-10.00%
30 Sep, 23	10	-
30 Jun, 23	10	66.67%
31 Mar, 23	6	-50.00%
31 Dec, 22	12	-7.69%
30 Sep, 22	13	8.33%
30 Jun, 22	12	50.00%
31 Mar, 22	8	-50.00%
31 Dec, 21	16	-

11 institutional shareholders have increased their position in CNTX stock as of 31 Mar 24 compared to 9 in the previous quarter (a 22.22% increase).

Institutional Reduced Positions Trend

Date	Reduced Positions	Change %
31 Mar, 24	2	100.00%
31 Dec, 23	1	-
30 Sep, 23	1	-50.00%
30 Jun, 23	2	-66.67%
31 Mar, 23	6	-
31 Dec, 22	6	-
30 Sep, 22	-	-100.00%
30 Jun, 22	1	-50.00%
31 Mar, 22	2	-
31 Dec, 21	-	-

2 institutional shareholders have reduced their position in CNTX stock as of 31 Mar 24 compared to 1 in the previous quarter (a 100.00% increase).

All Institutional Ownership Trend Data

Date	Holdings	Change %	Shares Outstanding	Change %	Ownership %	Change %	Increased Positions	Change %	Reduced Positions	Change %
31 Mar, 24	25	8.70%	3,935,132	10.59%	24.65%	4.96%	11	22.22%	2	100.00%
31 Dec, 23	23	4.55%	3,558,239	38.01%	22.29%	8.55%	9	-10.00%	1	-
30 Sep, 23	22	4.76%	2,578,256	15.16%	16.15%	8.21%	10	-	1	-50.00%
30 Jun, 23	21	10.53%	2,238,766	77.40%	14.02%	22.44%	10	66.67%	2	-66.67%
31 Mar, 23	19	-13.64%	1,262,007	-67.50%	7.90%	1.34%	6	-50.00%	6	-
31 Dec, 22	22	10.00%	3,882,945	-5.68%	24.32%	3.66%	12	-7.69%	6	-
30 Sep, 22	20	17.65%	4,116,702	13.04%	25.78%	4.96%	13	8.33%	-	-100.00%
30 Jun, 22	17	41.67%	3,641,962	25.39%	22.81%	6.89%	12	50.00%	1	-50.00%
31 Mar, 22	12	-25.00%	2,904,420	-18.17%	18.19%	1.51%	8	-50.00%	2	-
31 Dec, 21	16	-	3,549,370	-	34.76%	-	16	-	-	-

Context Therapeutics Insider Shareholders Trades

Open Market Insider Trades

Date	Name	Relation	Role	Transaction	Buy/Sell	Shares	Price	Value	Shares Held
Feb 21, 2023	Lehr Martin A.	director, officer	Chief Executive Officer	P-Purchase	Buy	5,823	$0.84	$4.90K	159,701
Feb 13, 2023	Lehr Martin A.	director, officer	Chief Executive Officer	P-Purchase	Buy	5,606	$0.87	$4.90K	153,878
Feb 06, 2023	Lehr Martin A.	director, officer	Chief Executive Officer	P-Purchase	Buy	5,040	$0.97	$4.90K	148,272
Jan 30, 2023	Lehr Martin A.	officer	Chief Executive Officer	P-Purchase	Buy	7,027	$0.70	$4.90K	143,232
Jan 23, 2023	Lehr Martin A.	officer	Chief Executive Officer	P-Purchase	Buy	6,839	$0.72	$4.90K	136,205
Jan 18, 2023	Lehr Martin A.	officer	Chief Executive Officer	P-Purchase	Buy	6,783	$0.74	$5.00K	129,366
Dec 19, 2022	Minai-Azary Jennifer Lynn	officer	Chief Financial Officer	P-Purchase	Buy	25,000	$0.74	$18.50K	40,000
Dec 19, 2022	Lehr Martin A.	officer	Chief Executive Officer	P-Purchase	Buy	20,000	$0.74	$14.80K	122,583
Dec 12, 2022	Levit Alex C.	officer	Chief Legal Officer, Corp. Sec	P-Purchase	Buy	6,000	$0.85	$5.09K	9,000
Aug 22, 2022	Lehr Martin A.	officer	Chief Executive Officer	P-Purchase	Buy	13,000	$1.85	$24.06K	102,583

Open Market Insider Buys

Date	Name	Relation	Role	Transaction	Buy/Sell	Shares	Price	Value	Shares Held
Feb 21, 2023	Lehr Martin A.	director, officer	Chief Executive Officer	P-Purchase	Buy	5,823	$0.84	$4.90K	159,701
Feb 13, 2023	Lehr Martin A.	director, officer	Chief Executive Officer	P-Purchase	Buy	5,606	$0.87	$4.90K	153,878
Feb 06, 2023	Lehr Martin A.	director, officer	Chief Executive Officer	P-Purchase	Buy	5,040	$0.97	$4.90K	148,272
Jan 30, 2023	Lehr Martin A.	officer	Chief Executive Officer	P-Purchase	Buy	7,027	$0.70	$4.90K	143,232
Jan 23, 2023	Lehr Martin A.	officer	Chief Executive Officer	P-Purchase	Buy	6,839	$0.72	$4.90K	136,205
Jan 18, 2023	Lehr Martin A.	officer	Chief Executive Officer	P-Purchase	Buy	6,783	$0.74	$5.00K	129,366
Dec 19, 2022	Minai-Azary Jennifer Lynn	officer	Chief Financial Officer	P-Purchase	Buy	25,000	$0.74	$18.50K	40,000
Dec 19, 2022	Lehr Martin A.	officer	Chief Executive Officer	P-Purchase	Buy	20,000	$0.74	$14.80K	122,583
Dec 12, 2022	Levit Alex C.	officer	Chief Legal Officer, Corp. Sec	P-Purchase	Buy	6,000	$0.85	$5.09K	9,000
Aug 22, 2022	Lehr Martin A.	officer	Chief Executive Officer	P-Purchase	Buy	13,000	$1.85	$24.06K	102,583

Insider Sells

Date	Name	Relation	Role	Transaction	Buy/Sell	Shares	Price	Value	Shares Held	Source

All Insider Owners Trades

Date	Name	Relation	Role	Transaction	Buy/Sell	Shares	Price	Value	Shares Held
Mar 22, 2024	Minai-Azary Jennifer Lynn	officer	Chief Financial Officer	A-Award	Buy	160,115	$1.07	$171.32K	160,115
Mar 22, 2024	Levit Alex C.	officer	Chief Legal Officer, Corp. Sec	A-Award	Buy	153,515	$1.07	$164.26K	153,515
Mar 22, 2024	Lehr Martin A.	director, officer	Chief Executive Officer	A-Award	Buy	291,402	$1.07	$311.80K	291,402
May 31, 2023	Kantoff Philip W.	director	-	A-Award	Buy	25,000	$0.87	$21.75K	25,000
May 31, 2023	West Linda	director	-	A-Award	Buy	25,000	$0.87	$21.75K	25,000
May 31, 2023	Stacey Jennifer Evans	director	-	A-Award	Buy	25,000	$0.87	$21.75K	25,000
May 31, 2023	BERMAN RICHARD J	director	-	A-Award	Buy	50,000	$0.87	$43.50K	50,000
Feb 21, 2023	Lehr Martin A.	director, officer	Chief Executive Officer	P-Purchase	Buy	5,823	$0.84	$4.90K	159,701
Feb 14, 2023	Levit Alex C.	officer	Chief Legal Officer, Corp. Sec	A-Award	Buy	151,505	$0.84	$127.37K	151,505
Feb 14, 2023	Lehr Martin A.	director, officer	Chief Executive Officer	A-Award	Buy	287,544	$0.84	$241.74K	287,544
Feb 14, 2023	Minai-Azary Jennifer Lynn	officer	Chief Financial Officer	A-Award	Buy	158,001	$0.84	$132.83K	158,001
Feb 13, 2023	Lehr Martin A.	director, officer	Chief Executive Officer	P-Purchase	Buy	5,606	$0.87	$4.90K	153,878
Feb 06, 2023	Lehr Martin A.	director, officer	Chief Executive Officer	P-Purchase	Buy	5,040	$0.97	$4.90K	148,272
Jan 30, 2023	Lehr Martin A.	officer	Chief Executive Officer	P-Purchase	Buy	7,027	$0.70	$4.90K	143,232
Jan 23, 2023	Lehr Martin A.	officer	Chief Executive Officer	P-Purchase	Buy	6,839	$0.72	$4.90K	136,205
Jan 18, 2023	Lehr Martin A.	officer	Chief Executive Officer	P-Purchase	Buy	6,783	$0.74	$5.00K	129,366
Dec 19, 2022	Minai-Azary Jennifer Lynn	officer	Chief Financial Officer	P-Purchase	Buy	25,000	$0.74	$18.50K	40,000
Dec 19, 2022	Lehr Martin A.	officer	Chief Executive Officer	P-Purchase	Buy	20,000	$0.74	$14.80K	122,583
Dec 12, 2022	Levit Alex C.	officer	Chief Legal Officer, Corp. Sec	P-Purchase	Buy	6,000	$0.85	$5.09K	9,000
Aug 22, 2022	Lehr Martin A.	officer	Chief Executive Officer	P-Purchase	Buy	13,000	$1.85	$24.06K	102,583

The last insider buy of CNTX was made by Lehr Martin A. on Feb 21 2023, buying 5,823 shares at $0.84 per share (worth $4.90K).

Context Therapeutics Insider Ownership Trends

All Insider Trades Trend

Date	Buy	Sell	Buy/Sell Ratio
Q1 2024	3	-	-
Q2 2023	4	-	-
Q1 2023	9	-	-
Q4 2022	3	-	-
Q3 2022	4	-	-
Q2 2022	7	-	-
Q1 2022	5	-	-
Q4 2021	15	22	68.18%
Q4 2020	-	-	-

3 total buy trades, and 0 total sell trades (buy/sell ratio of 0%) were made by Context Therapeutics's insiders, as of Q1 2024.

Open Market Insider Trades Trend

Date	Buy	Sell	Buy/Sell Ratio
Q1 2024	-	-	-
Q2 2023	-	-	-
Q1 2023	6	-	-
Q4 2022	3	-	-
Q3 2022	3	-	-
Q2 2022	-	-	-
Q1 2022	-	-	-
Q4 2021	4	-	-
Q4 2020	-	-	-

As of Q1 2024, Insider owners conducted 0 open market buy trades and 0 open market sell trades of Context Therapeutics's stocks.

Context Therapeutics Peer Ownership

Ticker	Company
ZURA	Zura Bio Limited
GRCL	Gracell Biotechnologies Inc.
TERN	Terns Pharmaceuticals, Inc.
ABOS	Acumen Pharmaceuticals, Inc.
SPRO	Spero Therapeutics, Inc.
NXTC	NextCure, Inc.
VECT	VectivBio Holding AG
INAB	IN8bio, Inc.
XFOR	X4 Pharmaceuticals, Inc.
INZY	Inozyme Pharma, Inc.
WVE	Wave Life Sciences Ltd.
DAWN	Day One Biopharmaceuticals, Inc.
ANNX	Annexon, Inc.
AMLX	Amylyx Pharmaceuticals, Inc.
CTMX	CytomX Therapeutics, Inc.
BOLT	Bolt Biotherapeutics, Inc.
NLTX	Neurogene Inc.
CHRS	Coherus BioSciences, Inc.
ASMB	Assembly Biosciences, Inc.

CNTX Ownership FAQ

Who Owns Context Therapeutics?

Context Therapeutics is owned by institutional shareholders (24.65%), insiders (2.78%), and public (72.57%). The largest institutional shareholder of Context Therapeutics is OPALEYE MANAGEMENT INC. (6.94% of total shares) and the top mutual fund owner is BRIDGEWAY FUNDS INC (0.04% of total shares).

Who are the major institutional shareholders of Context Therapeutics?

Context Therapeutics's major institutional shareholders are OPALEYE MANAGEMENT INC., ALLY BRIDGE GROUP (NY) LLC, VANGUARD GROUP INC, AFFINITY ASSET ADVISORS, LLC, and UBS OCONNOR LLC. The top five shareholders own together 19.15% of the company's share outstanding.

How many Context Therapeutics shareholders are there?

As of Mar 2024, there are 25 institutional shareholders of Context Therapeutics.

What percentage of Context Therapeutics is owned by OPALEYE MANAGEMENT INC?

OPALEYE MANAGEMENT INC owns 1.11M shares of Context Therapeutics, representing 6.94% of the company's total shares outstanding, valued at $1.53M (as of Mar 2024).

What percentage of Context Therapeutics is owned by ALLY BRIDGE GROUP (NY) LLC?

As of Mar 2024, ALLY BRIDGE GROUP (NY) LLC holds 725.95K shares of Context Therapeutics (CNTX), compromising 4.55% of the company, valued at $1M.

What percentage of Context Therapeutics is owned by VANGUARD GROUP INC?

VANGUARD GROUP INC is the third largest holder of Context Therapeutics. The company owns 598.3K of the company's shares outstanding (worth $825.66K).